

*The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.*

**Xanax XR® (alprazolam) extended-release tablets, 2mg and 3mg**

<b>NDC #</b>	<b>Material Description/ Strength</b>	<b>Size</b>	<b>Lot No</b>	<b>Expiry</b>
0009-0066-07	Xanax XR® (alprazolam) extended-release tablets, 2mg		DX7985	2023 Feb 28
0009-0068-07	Xanax XR® (alprazolam) extended-release tablets, 3mg	60 tablets in Bottle	DX7983	2023 Feb 28

Pfizer Pharmaceuticals LLC (a Viartis company) is conducting a recall at the retail level of the above identified lots of Xanax XR® (alprazolam) extended-release tablets, 2mg and 3 mg. Lot DX7983 is being recalled due to dissolution results that were found out of specification (OOS) and lot DX7985 is being recalled due to lower than typical dissolution values during shelf-life.

These lots were distributed in the US between August 2020 and March 2022. Potential risk to patients arising from this issue is unlikely. To date, no adverse events for the subject product lots have been received.